De-Risk Your Early Phase Programs
Lipid based drug delivery systems (LBDDS) are the most studied and understood bioavailability enhancing solutions and have been used to deliver more than 60 new drug molecules1 to the global market. The versatility and range of LBDDS are customizable to meet the demands of increasingly poorly soluble drug candidates. In addition to addressing a molecule’s physicochemical characteristics, LBDDS screening is fast, simple in the preclinical setting, and its scalability is relatively straightforward. This webinar discuss how to fully characterize and assess molecule developability, enhance the solid state chemistry of API, and apply necessary solubility enhancing technologies to derisk early phase programs.